Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-α in menstrual endometrium and effluent in women with menorrhagia

Human Reproduction

Volumn 21, Issue 8, 2006, Pages 2158-2166

  Malik, Shazia ^a,b   Day, Kate ^a   Perrault, Isabelle ^a   Charnock Jones, D Stephen ^a   Smith, Stephen K ^a  

^a DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Blood vessels; Endometrium; Matrix metalloproteinase; Menorrhagia; VEGF A

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOMETRIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33747872038     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del089     Document Type: Article

References (66)

1. Abberton KM, Taylor NH, Healy DL and Rogers PA (1999) Vascular smooth muscle cell proliferation in arterioles of the human endometrium. Hum Reprod 14,1072-1079.
2. Arkonac BM, Foster LC, Sibinga NES, Patterson C, Lai K, Tsai JC, Lee ME, Perrella MA and Haber E (1998) Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem 273,4400-4405.
3. Bausero P, Cavaille F, Meduri G, Freitas S and Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: Production and target sites, and hormonal regulation. Angiogenesis 2,167-182.
4. Bendeck MP, Zempo N, Clowes AW, Galardy RE and Reidy MA (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75,539-545.
5. Blum S, Issbruker K, Willuweit A, Hehlgans S, Lucerna M, Mechtcheriakova D, Walsh K, von der Ahe D, Hofer E and Clauss M (2001) An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 276,33428-33434.
6. Bonnar J and Sheppard BL (1996) Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313,579-582.
7. Brenner RM, Nayak NR, Slayden OD, Critchley HO and Kelly RW (2002) Premenstrual and menstrual changes in the macaque and human endometrium: relevance to endometriosis. Ann N Y Acad Sci 955,60-74; Discussion 86-88,396-406.
8. Burbridge MF, Coge F, Galizzi JP, Boutin JA, West DC and Tucker GC (2002) The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 5,215-226.
9. Cameron IT, Haining R, Lumsden MA, Reid Thomas V and Smith SK (1990) The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics Gynecol 76,85-88.
10. Carlson KJ, Nichols DH and Schiff I (1993) Indications for hysterectomy. N Engl J Med 328,856-860.
11. Cederholm-Williams SA, Rees MC and Turnbull AC (1984a) Consumption of fibrinolytic proteins in menstrual fluid from women with normal menstrual blood loss. J Clin Pathol 37,879-881.
12. Cederholm-Williams SA, Rees MCP and Turnbull AC (1984b) Examination of certain coagulation factors in menstrual fluid from women with normal blood loss. Thromb Haemost 52,224-225.
13. Chen DB, Yang ZM, Hilsenrath R, Le SP and Harper MJ (1995) Stimulation of prostaglandin (PG) F2 alpha and PGE2 release by tumour necrosis factor-alpha and interleukin-1 alpha in cultured human luteal phase endometrial cells. Hum Reprod 10,2773-2780.
14. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162,156-159.
15. Christiaens G, Sixma JJ and Haspels AA (1980) Morphology of haemostasis in menstrual endometrium. Br J Obstet Gynaecol 87,425-439.
16. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R and Charnock-Jones DS (1998) A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59,1540-1548.
17. Clauss M, Sunderkotter C, Sveinbjornsson B, Hippenstiel S, Willuweit A, Marino M, Haas E, Seljelid R, Scheurich P, Suttorp N et al. (2001) A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97,1321-1329.
18. Cornet PB, Galant C, Eeckhout Y, Courtoy PJ, Marbaix E and Henriet P (2005) Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J Clin Endocrinol Metab 90,1001-1011.
19. English WR, Holtz B, Vogt G, Knauper V and Murphy G (2001) Characterization of the role of the "MT-loop": An eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J Biol Chem 276,42018-42026.
20. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW and Davidge ST (2000) Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87,670-676.
21. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge-ST and Filep JG (2001) Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1 [1-32]. Faseb J 15,2230-2240.
22. Frater-Schroder M, Risau W, Hallmann R, Gautschi P and Bohlen P (1987) Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84,5277-5281.
23. Freitas S, Meduri G, Le Nestour E, Bausero P and Perrot-Applanat M (1999) Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium. Biol Reprod 61,1070-1082.
24. Galis ZS and Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90,251-262.
25. Gannon MJ, Day P, Hammadieh N and Johnson N (1996) A new method for measuring menstrual blood loss and its use in screening women before endometrial ablation. Br J Obstet Gynaecol 103,1029-1033.
26. Gargett CE, Lederman F, Heryanto B, Gambino LS and Rogers PA (2001) Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils. Hum Reprod 16,1065-1075.
27. Graubert MD, Ortega MA, Kessel B, Mortola JF and Iruela-Arispe ML (2001) Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1. Am J Pathol 158,1399-1410.
28. Hastings JM, Licence DR, Burton GJ, Charnock-Jones DS and Smith SK (2003) Soluble vascular endothelial growth factor receptor 1 inhibits edema and epithelial proliferation induced by 17beta-estradiol in the mouse uterus. Endocrinology 144,326-334.
29. Haynes DM and Wolfe WM (1970) Tubal sterilization in an indigent population. Report of fourteen years' experience. Am J Obstet Gynecol 106,1044-1053.
30. He Y, Smith SK, Day KA, Clark DE, Licence DR and Charnock-Jones DS (1999) Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13,537-545.
31. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A and Weich HA (2000) Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80,443-454.
32. Hornung D, Lebovic DI, Shifren JL, Vigne JL and Taylor RN (1998) Vectorial secretion of vascular endothelial growth factor by polarized human endometrial epithelial cells. Fertil Steril 69,909-915.
33. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47,617-623.
34. Johnson C, Sung HJ, Lessner SM, Fini ME and Galis ZS (2004) Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ Res 94,262-268.
35. Kendall RL and Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90,10705-10709.
36. Kooy J, Taylor NH, Healy DL and Rogers PA (1996) Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation. Hum Reprod 11,1067-1072.
37. Kroll J and Waltenberger J (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272,32521-32527.
38. Lockwood CJ, Krikun G, Papp C, Toth-Pal E, Markiewicz L, Wang EY, Kerenyi T, Zhou X, Hausknecht V, Papp Z et al. (1994) The role of progestationally regulated stromal cell tissue factor and type-1 plasminogen activator inhibitor (PAI-1) in endometrial hemostasis and menstruation. Ann N Y Acad Sci 734,57-79.
39. Ludwig H, Metzger H and Frauli M (1976) The re-epitheliazation of endometrium after menstrual desquamation. Arch Gynakol 221,51-60.
40. Majka S, McGuire PG and Das A (2002) Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 43,260-266.
41. Markee JE (1940) Menstruation in intraocular endometrial transplants in the rhesus monkey. Contributions Embryol 28,219-308.
42. Mechtcheriakova DSG, Lucerna M, Clauss M, De Martin R, Binder BR and Hofer E (2001) Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 15,230-242.
43. Nilsson L and Rybo G (1971) Treatment of menorrhagia. Am J Obstet Gynecol 110,713-720.
44. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF and Lopez DM (2003) Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: Role of vascular endothelial growth factor. J Immunol 171,4340-4351.
45. Papapetropoulos A, Garcia-Cardena G, Madri JA and Sessa WC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100,3131-3139.
46. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee M-E and Haber E (1996) Downregulation of vascular endothelial growth factor receptors tumor necrosis factor-α in cultured human vascular endothelial cells. J Clin Invest 98,4900-4906.
47. Preston JT, Cameron IT, Adams EJ and Smith SK (1995) Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 102,401-406.
48. Rees MCP, Dunhill MS, Anderson ABM and Turnbull AC (1984) Quantitative uterine histology during the menstrual cycle in relation to measured menstrual blood loss. Br J Obstet Gynaecol 91,662-660.
49. Rigot V, Marbaix E, Lemoine P, Courtoy PJ and Eeckhout Y (2001) In vivo perimenstrual activation of progelatinase B (proMMP-9) in the human endometrium and its dependence on stromelysin 1 (MMP-3) ex vivo. Biochem J 358,275-280.
50. Rodgers WH, Matrisian LM, Giudice LC, Dsupin B, Cannon P, Svitek C, Gorstein F and Osteen KG (1994) Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 94,946-953.
51. Rybo G (1966) Clinical and experimental studies on menstrual blood loss. Acta Obstet Gynecol Scand 45 (Suppl. 7),1-23.
52. Salamonsen LA, Zhang J, Hampton A and Lathbury L (2000) Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 15 (Suppl. 3), 112-119.
53. Sawicki G, Salas E, Murat J, Miszta-Lane H and Radomski MW (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386,616-619.
54. Shalaby MR, Laegreid WW, Ammann AJ and Liggitt HD (1989) Tumor necrosis factor-alpha-associated uterine endothelial injury in vivo.Influence of dietary fat. Lab Invest 61,564-570.
55. Sharkey AM, Day K, McPherson A, Malik S, Licence D, Smith SK and Charnock-Jones DS (2000) Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab 85,402-409.
56. Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A and Levy BI (2001) Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: Role in ischemia-induced angiogenesis. Circ Res 89,259-264.
57. Smith SK, Abel MH, Kelly RW and Baird DT (1981a) A role for prostacyclin (PGi2) in excessive menstrual bleeding. Lancet 1,522-524.
58. Smith SK, Abel MH, Kelly RW and Baird DT (1981b) Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 88,434-442.
59. Soini Y, Alarakkola E and Autio-Harmainen H (1997) Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 28,220-226.
60. Sounni NE, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, Galvez BG, Gilles C, Frankenne F, Murphy G et al. (2004) Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 279,13564-13574.
61. Tabibzadeh S (1996) The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Mol Hum Reprod 2,77-92.
62. Tabibzadeh S, Zupi E, Babaknia A, Liu R, Marconi D and Romanini C (1995) Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF alpha in human endometrium. Hum Reprod 10,277-286.
63. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM and Werb Z (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93,411-422.
64. Wary KK, Thakker GD, Humtsoe JO and Yang J (2003) Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2,25.
65. Zhang J and Salamonsen LA (2002) In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87,2346-2351.
66. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews NW, Bahou WF and Jesty J (1998) Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 75,780-786.